Navigation Links
Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline
Date:6/28/2010

MAPLE GROVE, Minn., June 28 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. today announced an agreement with Ikano Therapeutics, Inc. to obtain exclusive global rights to ITI-111, Ikano's nasal midazolam.  Under terms of the agreement, Upsher-Smith will assume all further development, testing and clinical study of nasal midazolam as an orphan drug for the management of acute repetitive seizure (ARS) in patients with epilepsy.  Upon successful completion of development and regulatory approval, Upsher-Smith will commercialize the product, initially in the U.S. market.

"Currently, epilepsy patients experiencing cluster seizures or acute repetitive seizures have limited options for treatment," said Dr. Jacqueline French, Professor of Neurology at the New York University Comprehensive Epilepsy Center.  "A product such as nasal midazolam could represent an additional treatment option for these patients, and has the potential to address a significant unmet need."

Some patients with epilepsy periodically experience episodes of ARS that are distinct from their usual seizure pattern.  There have been no new FDA-approved products targeting ARS in nearly 15 years.(1)

"The addition of nasal midazolam to our growing development portfolio represents a significant milestone in helping us achieve our vision of building a leadership position in the central nervous system field," said Mark Evenstad, President of Upsher-Smith.  "We will continue to focus our efforts on the development of products that address significant unmet needs for patients with epilepsy, Parkinson's disease and Alzheimer's disease."

Upsher-Smith's development programs for the management of epile
'/>"/>

SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Upsher-Smith Announces New Formulation of PreNexa(R) Prenatal Vitamins
2. New Data: Cholesterol Management Analysis of Upsher-Smiths Slo-Niacin(R) Tablets in Combination with Lipitor(R)
3. Upsher-Smith Announces Milestone in Development of CNS Strategy
4. Upsher-Smith Introduces New Formulation of PreNexa® Prenatal Vitamins
5. Upsher-Smith Laboratories Announces Initiation of Phase III Clinical Trial of USL255 (Extended-Release Topiramate) for Adjunctive Treatment of Partial-Onset Epilepsy
6. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
7. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
8. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
9. Romark Laboratories Raises $18 Million in Institutional Financing
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LAVAL, Quebec , March 27, 2015  Valeant ... announced today the closing of its previously announced registered ... States (the "Offering"). Pursuant to the Offering, ... of $199.00 per share, for aggregate gross proceeds of ... filed with the U.S. Securities and Exchange Commission a ...
(Date:3/27/2015)... March 27, 2015  RXi Pharmaceuticals Corporation ... LLC, today announced that they have entered ... novel and proprietary sd-rxRNA® technology for use ... collaboration has the potential to result in ... treatments that could be a significant step ...
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3
... , , , ... leading developer of medical device technology for the safe ... new Webinar program supporting its culture of safety initiative ... "A Culture of Safety in Pharmacy: Lessons Learned," features ...
... , MOUNTAIN VIEW, Calif., Dec. 29 VIVUS, Inc. (Nasdaq: ... therapies to address unmet needs in obesity, diabetes and sexual ... been submitted to the U.S. Food and Drug Administration (FDA) ... of obesity, including weight loss and maintenance of weight loss, ...
Cached Medicine Technology:Baxa Corporation to Sponsor Free Culture of Safety Webinar 2Baxa Corporation to Sponsor Free Culture of Safety Webinar 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5
(Date:3/27/2015)... 27, 2015 On February 21, ... in the Stardust Penthouse on the rooftop of ... Angeles’ leading sustainable product TV and film placement ... day-long event, which featured some of the world’s ... products and services. , “We were honored to ...
(Date:3/27/2015)... March 27, 2015 According to a ... ), the plate and screw market in Europe is ... generic plate and screw segment. Price decreases are being ... representing almost 50% of the total European trauma device ... the total market value, year after year. , ...
(Date:3/27/2015)... 2015 According to Health Day ... with Neonatal Abstinence Syndrome (NAS) are causing alarm for ... painful withdrawal process for a month of their lives- ... diarrhea, and vomiting. The condition is precipitated by drug ... addiction treatment (and employing medically assisted drug treatment) will ...
(Date:3/27/2015)... March 27, 2015 When struck with ... hard to know where to begin. The latest ... trucking accident attorney, offers accident victims a clear and ... assistance to ensure their personal injury claim is seen ... describing the first actions that should be taken immediately ...
(Date:3/27/2015)... Texas (PRWEB) March 27, 2015 ... Glutathione Industry is a professional and in-depth study ... glutathione market with a focus on the ... overview of the industry including definitions, classifications, applications ... is provided for both the international and Chinese ...
Breaking Medicine News(10 mins):Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 2Health News:Glutathione Industry International and China Market Analysis Report 2015-2020 3
... nutritional supplements ... in North ... Alliance,(CWA), experts in designing custom wellness programs for consumers and,corporations, ... announcement was made by biochemist, Lyle MacWilliam, author,of the recently ...
... many,people who have called and asked how they could help, ... with Tony Snow,s children,s education and,expenses., Jill Snow, Tony,s ... Kendall, Robbie and Kristi, as beneficiaries. Donations can,be made directly ... check,made payable to the "Tony Snow Family Trust" to:, ...
... ANGELES, July 14 The Cooperative of American,Physicians, ... exceeded 10,000 physicians., "Surpassing the 10,000 member ... CEO James L. Weidner. "The physicians who founded,CAP ... They believed that,physicians working together could find a ...
... with upbeat outlook, but same did not hold true for women ... had a lower risk of dying from heart disease turned out ... their conventional risk factors showed. , The death rate for men ... of those who listed themselves as being at average risk, said ...
... The Medical Device,Manufacturers Association (MDMA), a national trade ... the Board of Directors at the,MDMA Annual Meeting ... http://www.newscom.com/cgi-bin/prnh/20041004/MDMALOGO ), "I am honored to ... Manufacturers,Association," stated Root. "MDMA has a long history ...
... in heart and travels to the brain, heparin more risky, ... widely prescribed blood-thinning drug heparin is associated with an increased ... cardioembolic stroke, new research shows. , But another thinning ... in the same group of patients. , This finding led ...
Cached Medicine News:Health News:Vitalize(TM) Receives Top Multivitamin Rating 2Health News:Cooperative of American Physicians Membership Tops 10,000 2Health News:Optimism About Heart Risk Pays Off 2Health News:Vascular Solutions CEO Elected to MDMA Board of Directors 2Health News:Warfarin Safer Than Heparin for Some Strokes 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: